AnX Robotica Appoints Industry Veterans to Leadership Team, Continues Innovation in Gastrointestinal Diagnostics

Ruediger Nigbur has been promoted to VP and general manager for Europe, the Middle East, and Africa, and Ray Bengermino has been appointed VP of U.S. sales. Their leadership comes at a pivotal time for AnX Robotica, said the company, which holds over 200 patents in advanced medical technology.

Plano-based AnX Robotica, a leader in advanced gastrointestinal visualization technologies, has announced the appointment of two industry veterans to its leadership team, according to a recent news release.

Ruediger Nigbur, who joined AnX Robotica in 2020 as managing director for Europe, the Middle East, and Africa (EMEA), has been promoted to vice president and general manager for the same regions. Ray Bengermino, senior director of sales in the U.S., has been appointed vice president of U.S. sales.

Nigbur brings over 20 years of experience and has been instrumental in developing AnX Robotica’s operations and distribution channels in EMEA. Bengermino, who built the U.S. sales organization from scratch, has successfully led his team to capture market share with the NaviCam Small Bowel Capsule Endoscopy with ProScan, the first FDA and CE Marked AI-assisted reading tool for small bowel capsule endoscopy.

“These appointments reflect our commitment to driving forward with excellence and leadership in the field,” Joe Xiao, co-founder, president, and CEO of AnX Robotica, said in a statement. “Their extensive experience and proven track records in the industry are invaluable as we continue to expand our global presence and innovate gastrointestinal visualization technologies.”

Pioneering tech for GI health

Founded in 2019, AnX Robotica is a pioneering force in advanced medical technology, committed to providing the medical community with user-friendly devices for diagnostic and therapeutic purposes. The company was co-founded by Xiao, who serves as president and CEO, Chief Technology Officer David Duan, and Thomas Wang, a board member. Together, the trio brings a wealth of expertise in medical technology, magnetism, materials science, optoelectronic technology, and digital processing to the company.

According to the company’s website, AnX Robotica’s roots trace back to 2008, when its founders began designing and building the basic Robotic Capsule Endoscopy technology in Silicon Valley. The company was officially established in 2019 in the U.S., following a commercial agreement to share products and technologies with ANKON Medical Technologies, which was founded in 2009 and was the first company in the world to commercialize a “Magnetically Controlled Capsule Endoscope System.”

AnX Robotica has been making pioneering strides in the industry with its innovative products and technologies. The company recently announced that a publication on May 13, 2024, validated the clinical benefits of using ProScan, its revolutionary AI technology, in diagnosing small bowel bleeding faster and more accurately. This follows the FDA clearance for expanded indications of its NaviCam Small Bowel Video Capsule Endoscopy on January 15, 2024, and the FDA clearance for ProScan, a groundbreaking AI-assisted reading tool for small bowel video capsule endoscopy, on January 3, 2024.

Additionally, AnX Robotica announced expanded indications of its Magnetically Controlled Capsule Endoscopy on November 1, 2023.

More than 200 patents granted or pending

According to the company’s website, AnX Robotica has a strong intellectual property portfolio, with more than 200 patents granted or applications pending. The company’s founders and leadership team have authored numerous patents in the field of advanced medical technology, showcasing their expertise and innovation in the development of cutting-edge diagnostic and therapeutic devices for gastrointestinal health.

Dallas Innovates has reported on the company’s patent activities between 2021 and 2023, highlighting several patents granted to AnX Robotica Corp. in the Dallas-Fort Worth-Arlington metro area. These patents include innovations in medical devices, such as an inflatable in-vivo capsule endoscope and other advanced gastrointestinal diagnostic tools.

Get on the list.
Dallas Innovates, every day.

Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.

One quick signup, and you’re done.
View previous emails.

R E A D   N E X T

  • The Advanced Research Projects Agency for Health—or ARPA-H— wants to enable 90% of eligible Americans to participate in clinical trials within 30 minutes of their homes. The agency officially launched its new Texas "customer experience" headquarters at Dallas' Pegasus Park on Thursday, which will be home base for the initiative.

  • Five Liters, an offshoot of Spark Biomedical, begins 'first-in-human' trials to explore wearable neurostimulation technology for managing inherited blood disorders and more. Parent Spark Biomedical is focused on its FDA-cleared wearable device for drug-free opioid withdrawal.

  • Drawing from his own powerful lesson after losing a multimillion-dollar deal, TransPharMed CEO Kirk Barnes helps founders and leaders to be primed and ready to connect when opportunity knocks. Will Magruder, VP of partnerships at MassChallenge, lends his expertise to crafting a "handshake pitch" in nine words or less. Here's how. Plus, the votes are in. MassChallenge announced its Handshake Pitch Winners at Pegasus Park: “We're the Tesla of jet skis,” “Net-zero concrete by 2050 by 2022," "We personalize treatment down to your genes," and more.

  • A 2-mile hot zone along the Southwestern Medical District in Dallas is getting a cool makeover. The city's biggest urban heat island is slated to be turned into a dedicated green space. See designs for the corridor, complete with a 10-acre park.

  • With only two known living female northern white rhinos left, Colossal Biosciences and BioRescue have joined forces to fend off a looming extinction of the species. At the cutting edge of science, they're harnessing genetic technologies to rewrite the rhino's fate.